Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
Clinical trial NCT04319224 · TERMINATED
Trial details
- NCT number
- NCT04319224
- Sponsor
- Jounce Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-10
- Primary completion
- 2023-01-03
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.